Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7898722 | 0.88 | XDH (0.50) | DPP4TSHRSLC7A5RAB9AMAPT | |
| Bromide SCHEMBL2068413 | 0.87 | CA12 (0.43) | RAB9AMAPTALDH1A1KMT2ACYP1A2 | |
| Bromide SCHEMBL8899989 | 0.84 | P4HB (0.46) | TSHRSLC7A5RAB9AMAPTL3MBTL1 | |
| Bromide SCHEMBL7292931 | 0.84 | MAPT (0.47) | TSHRSLC7A5RAB9AMAPTLMNA | |
| Bromide SCHEMBL10980300 | 0.84 | KDM4E (0.49) | TSHRSLC7A5RAB9AMAPTL3MBTL1 | |
| Bromide SCHEMBL8901631 | 0.84 | PPARG (0.43) | TSHRSLC7A5RAB9AMAPTL3MBTL1 | |
| Bromide SCHEMBL7902023 | 0.83 | CA1 (0.50) | TSHRSLC7A5RAB9AMAPTLMNA | |
| Bromide SCHEMBL11599708 | 0.83 | KDM4E (0.49) | TSHRSLC7A5RAB9AMAPTLMNA | |
| Bromide SCHEMBL2316144 | 0.80 | VCAM1 (0.49) | TSHRMAPTLMNAALDH1A1KMT2A | |
| Bromide SCHEMBL31123663 | 0.80 | DPP4 (0.42) | DPP4TSHRMAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | DPP4 4007/4885TSHR 339/4885SLC7A5 1025/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | DPP4 4007/4885TSHR 339/4885SLC7A5 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.